What is the proper method to switch an ADHD patient from Concerta 72 mg (methylphenidate) to Focalin (dexmethylphenidate)?

Switching from Concerta 72 mg to Focalin in ADHD

Direct Conversion Strategy

Start Focalin (dexmethylphenidate) at approximately half the total daily methylphenidate dose, which translates to 36 mg of Focalin XR once daily in the morning, then titrate based on response. 1

The conversion is based on the pharmacologic principle that dexmethylphenidate—the isolated d-threo-enantiomer of racemic methylphenidate—provides comparable efficacy at approximately half the dose of standard methylphenidate. 2, 3

Step-by-Step Conversion Protocol

Initial Dosing

• Discontinue Concerta 72 mg and initiate Focalin XR 30-40 mg once daily the following morning. 2
• The FDA-approved starting range for adults switching from other methylphenidate products is 10-40 mg daily, with your patient's high baseline dose (72 mg Concerta) justifying the upper end of this range. 1
• Clinical trials demonstrate that an average dose of 18.25 mg/day dexmethylphenidate provides efficacy equivalent to 32.14 mg/day racemic methylphenidate, supporting the 2:1 conversion ratio. 2

Titration Schedule

• Assess response after 1 week using standardized rating scales (teacher/parent SNAP or ADHD-RS). 4
• If symptom control is inadequate, increase by 10 mg weekly up to a maximum of 40 mg daily for Focalin XR. 3, 5
• The bimodal release profile of Focalin XR mimics two immediate-release doses given 4 hours apart, providing coverage for 10-12 hours post-dose. 3, 5

Key Pharmacokinetic Differences

Duration of Action

• Focalin XR may provide slightly shorter duration (10-12 hours) compared to Concerta's 12-hour coverage, particularly in late afternoon/evening hours. 3
• Laboratory classroom studies show Focalin XR demonstrates superior early-day efficacy (first 6 hours) compared to OROS methylphenidate (Concerta), but assessments 10-12 hours post-dose favor Concerta. 3
• If evening symptom coverage is inadequate, add immediate-release dexmethylphenidate 5-10 mg in mid-afternoon (no later than 2:00 PM to avoid insomnia). 6

Onset of Action

• Focalin XR achieves therapeutic effect within 0.5 hours of administration due to its immediate-release component, faster than Concerta's 90-minute onset. 4, 3

Monitoring Requirements

Cardiovascular Assessment

• Measure blood pressure and pulse at baseline and at each follow-up visit during titration. 4, 1
• Contraindications include uncontrolled hypertension, symptomatic cardiovascular disease, and tachyarrhythmias. 4, 1

Growth and Weight

• Weigh the patient at each visit to objectively monitor appetite suppression, which may be more pronounced with dexmethylphenidate due to its longer half-life compared to immediate-release products. 4
• Administer medication with meals and recommend high-calorie evening snacks if weight loss occurs. 6

Symptom Assessment

• Use teacher and parent rating scales (ADHD-RS, SNAP, or Conners) at weekly intervals during titration. 4
• Specifically assess for late-afternoon symptom rebound between 4-6 PM, which may indicate need for supplemental immediate-release dosing. 6

Common Pitfalls and Management

Insomnia

• The most frequent adverse effect with dexmethylphenidate is sleep-onset difficulty, occurring more often than with racemic methylphenidate due to the isolated d-isomer's longer duration. 5, 7
• If insomnia develops, move the morning dose earlier or reduce the dose by 10 mg rather than discontinuing. 6

Inadequate Evening Coverage

• Patients previously stable on Concerta 72 mg may experience symptom return in late afternoon/evening due to Focalin XR's shorter duration. 3
• The solution is adding immediate-release dexmethylphenidate 5-10 mg at 1:00-2:00 PM, timed 4-6 hours after the morning dose to provide seamless coverage. 6

Appetite Suppression

• Dexmethylphenidate causes decreased appetite in up to 30% of patients, potentially more than racemic methylphenidate. 5, 7
• Administer with breakfast, offer medication-free weekends if clinically appropriate, and provide calorie-dense foods when appetite returns in evening. 6

Alternative Approach: Gradual Cross-Titration

If the patient has a history of poor tolerability to medication changes:

• Week 1: Reduce Concerta to 54 mg, add Focalin XR 20 mg
• Week 2: Discontinue Concerta, increase Focalin XR to 30-40 mg
• Week 3+: Titrate Focalin XR by 10 mg weekly based on response

This approach is not evidence-based but may reduce the risk of symptom exacerbation during the transition period. 4

Abuse Potential Considerations

• Assess personal and family history of substance use disorders before prescribing, as both formulations are Schedule II controlled substances. 1
• Focalin XR capsules can be opened and contents sprinkled on applesauce, which does not alter the extended-release properties but may facilitate misuse. 7, 8
• Educate patients about proper storage and the risks of diversion, particularly in adolescents and young adults. 6, 1

When to Consider Switching Back

• 41% of medication-naive adults require switching between methylphenidate and amphetamine families due to poor tolerability within 90 days. 9
• If the patient experiences intolerable adverse effects (severe insomnia, anxiety, appetite suppression) or inadequate efficacy after 4 weeks at optimal Focalin XR dosing, consider switching to an amphetamine-based stimulant rather than returning to Concerta. 9
• Baseline predictors of poor response are limited, but patients with higher intrusive symptoms may be more likely to require switching. 9